Kinetics of Targeted Phage Rescue in a Mouse Model of Systemic Escherichia coli K1
- PMID: 30105246
- PMCID: PMC6076946
- DOI: 10.1155/2018/7569645
Kinetics of Targeted Phage Rescue in a Mouse Model of Systemic Escherichia coli K1
Abstract
Escherichia (E.) coli K1 strains remain common causative agents of neonatal sepsis and meningitis. We have isolated a lytic bacteriophage (ΦIK1) against E. coli strain IHE3034 and tested its specificity in vitro, as well as distribution and protective efficacy in vivo. The phage was shown to be specific to the K1 capsular polysaccharide. In the lethal murine model, a high level of protection was afforded by the phage with strict kinetics. A single dose of 1 x 108 phage particles administered 10 and 60 minutes following the bacterial challenge elicited 100 % and 95 % survival, respectively. No mice could be rescued if phage administration occurred 3 hours postinfection. Tissue distribution surveys in the surviving mice revealed that the spleen was the primary organ in which accumulation of active ΦIK1 phages could be detected two weeks after phage administration. These results suggest that bacteriophages have potential as therapeutic agents in the control of systemic infections.
Figures




Similar articles
-
Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia.Int J Mol Med. 2006 Feb;17(2):347-55. Int J Mol Med. 2006. PMID: 16391836
-
Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15.Antimicrob Agents Chemother. 2012 Jul;56(7):3568-75. doi: 10.1128/AAC.06330-11. Epub 2012 Apr 9. Antimicrob Agents Chemother. 2012. PMID: 22491690 Free PMC article.
-
Treatment of Highly Virulent Extraintestinal Pathogenic Escherichia coli Pneumonia With Bacteriophages.Crit Care Med. 2015 Jun;43(6):e190-8. doi: 10.1097/CCM.0000000000000968. Crit Care Med. 2015. PMID: 25803649
-
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli.Pediatr Res. 1976 Feb;10(2):82-7. doi: 10.1203/00006450-197602000-00002. Pediatr Res. 1976. PMID: 1107953 Review.
-
Phage therapy targeting Escherichia coli-a story with no end?FEMS Microbiol Lett. 2016 Nov;363(22):fnw256. doi: 10.1093/femsle/fnw256. Epub 2016 Nov 9. FEMS Microbiol Lett. 2016. PMID: 27974392 Review.
Cited by
-
Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens.Antibiotics (Basel). 2021 Jun 4;10(6):672. doi: 10.3390/antibiotics10060672. Antibiotics (Basel). 2021. PMID: 34199889 Free PMC article. Review.
-
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities.Bioengineering (Basel). 2025 Apr 29;12(5):469. doi: 10.3390/bioengineering12050469. Bioengineering (Basel). 2025. PMID: 40428088 Free PMC article. Review.
-
Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases.Int J Clin Pract. 2022 Oct 3;2022:4913146. doi: 10.1155/2022/4913146. eCollection 2022. Int J Clin Pract. 2022. PMID: 36263241 Free PMC article. Review.
-
Progress and Pitfalls of Bacteriophage Therapy in Critical Care: A Concise Definitive Review.Crit Care Explor. 2021 Mar 8;3(3):e0351. doi: 10.1097/CCE.0000000000000351. eCollection 2021 Mar. Crit Care Explor. 2021. PMID: 33786430 Free PMC article. Review.
-
Isolation and Characterization of a Novel Lytic Bacteriophage against the K2 Capsule-Expressing Hypervirulent Klebsiella pneumoniae Strain 52145, and Identification of Its Functional Depolymerase.Microorganisms. 2021 Mar 21;9(3):650. doi: 10.3390/microorganisms9030650. Microorganisms. 2021. PMID: 33801047 Free PMC article.
References
-
- Hall M. J., Williams S. N., DeFrances C. J., Golosinskiy A. Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief. 2011;(62):1–8. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical